Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as <scp>l</scp>-Glutamine Replacements Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics Substituted Benzamide Inhibitors of Human Rhinovirus 3C Protease:  Structure-Based Design, Synthesis, and Biological Evaluation Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics New anti-viral drugs for the treatment of the common cold Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease Small peptidic aldehyde inhibitors of human rhinovirus 3C protease Non-covalent inhibitors of rhinovirus 3C protease In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease